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Mitchell Goldman, M.D., Bruce A. Mueller, Pharm.D., FCCP, and Kevin M. Sowinski, Pharm.D., FCCP
Study Objective.  To characterize and compare the pharmacokinetics of
levofloxacin in men and women after systemic administration.
Design.  Prospective, open-label, parallel group pharmacokinetic study.
Setting.  University research center.
Subjects. Eleven healthy men and nine healthy women stratified by body
mass index.
Intervention.  Subjects received levofloxacin as a single 500-mg intravenous
dose.  Serum and urine were collected over 36 hours.
Measurements and Main Results.  Levofloxacin concentrations were
determined by high-performance liquid chromatography with ultraviolet
detection.  Pharmacokinetic analysis was performed with ADAPT II
software (University of Southern California, Los Angeles, CA).  Median
(range) body mass index was 23.2 kg/m2 (19.9–28.3 kg/m2) for men and
23.6 kg/m2 (16.0–32.4 kg/m2) for women (p=0.67).  A two-compartment
model best fit the pharmacokinetic data:  median (range) R2 was 0.996
(0.990–0.999).  Women had a 24% greater exposure to levofloxacin, with a
significantly smaller steady-state volume of distribution (p<0.01) and a
slower clearance (p<0.01).
Conclusions. Differences exist in the disposition of levofloxacin between
healthy men and women after systemic administration.  Fixed intravenous
doses of levofloxacin will lead to greater drug exposure in women.  Thus,
women may have more of an increased risk of fluoroquinolone toxicity
than men, and men may need higher doses to achieve similar drug efficacy
than women.  Levofloxacin dosage adjustments based on sex should be
considered on an individual basis.
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Fluoroquinolones are broad-spectrum anti-
biotics commonly used in the treatment of
community-acquired pneumonia, among several
other infections.  They are generally well
tolerated, although central nervous system and
gastrointestinal adverse effects are common.1, 2
Observational data suggest that women may have
a greater frequency of these adverse effects with
certain fluoroquinolone antibiotics than do
men.3, 4 This increased toxicity in women may be
attributed to an underlying disposition or
response difference to fluoroquinolones between
the sexes.
Previous reports indicate that women have
increased maximum serum concentrations (Cmax)
and a greater exposure to several fluoro-
quinolones.5–10 In most of these studies, the
estimated volume of distribution of the
compound of interest was found to be smaller in
women compared with that in men but was
attenuated when normalized to body weight.
Other studies report an absence of a sex-related
effect on fluoroquinolone disposition when
pharmacokinetic parameters are normalized to
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total body weight, although none of the studies
reported pharmacokinetic parameters unadjusted
for weight.2, 11, 12 Thus, available data suggest that
because of smaller body weights, women may be
exposed to higher plasma fluoroquinolone
concentrations than are men when equal doses
are administered.  Despite body composition
differences, however, to our knowledge, relation-
ships between fluoroquinolone pharmacokinetics
and total body weight have not been investigated
in men and women to justify weight normal-
ization of pharmacokinetic parameters between
the sexes.
We previously published the sex-related effects
on the pharmacokinetics of ofloxacin
administered as a single 400-mg oral dose in
male and female volunteers.10 Consistent with
previous fluoroquinolone studies, the apparent
steady-state volume of distribution (Vss) was
significantly lower in women than in men, and
after weight adjustment the difference was
attenuated and no longer statistically significant.
Of particular interest, data from that study
suggest that differences may exist in the relation-
ship between the apparent Vss of ofloxacin and
total body weight in men and women.  In men, a
strong positive relationship between total body
weight and the apparent Vss was observed.  In the
women, however, no apparent relationship was
noted between Vss and total body weight.  If a
distinct relationship exists between the sexes,
pharmacokinetic parameter normalization to
total body weight may be inappropriate for
ofloxacin.  Since that study was performed after
administration of an oral dose, differences in the
clearance and Vss could not be distinguished
from potential differences in oral bioavailability.
Levofloxacin, the pharmacologically active S-
enantiomer of racemic ofloxacin, is frequently
used in clinical practice, but potential sex-based
disposition differences after intravenous
administration have not been established.2 Based
on observations from the ofloxacin study, we
hypothesized that sex-based differences exist in
the pharmacokinetics of levofloxacin after
systemic administration.  Therefore, we sought to
investigate the pharmacokinetics of intravenous
levofloxacin in a group of men and women
stratified by body mass index.  An additional aim
was to justify a weight-based normalization of
pharmacokinetic parameter estimates by
assessing the relationships between body weight
and composition with systemic clearance (Cls)
and apparent Vss in men and women.
Methods
Study Subjects
Men were enrolled without restriction into one
of three groups stratified by body mass index:
less than 20 kg/m2, 20–25 kg/m2, and greater
than 25 kg/m2. Women were matched to the men
based on the stratified groups to ensure similar
numbers of men and women in each group.  The
stratification procedure was implemented to
ensure similar body mass indexes were observed
between male and female study subjects at study
completion.  Healthy, nonsmoking male and
female volunteers aged 18–40 years were
recruited for study participation.
An initial interview was conducted to ascertain
information regarding the subject’s medical
history, current use of drugs, and history of
allergies.  Subjects were excluded if they were
taking any drugs, including over-the-counter
drugs within 24 hours before the study visit.
Premenopausal women with a history of a regular
menstrual cycle and not using any hormone-
containing contraceptive methods were eligible
for study participation.  Women were instructed
to use abstinence or effective barrier contra-
ceptive methods from the initial screening until a
minimum of 1 week after the study period.  Two
urine pregnancy tests were obtained for each
woman, one during screening and one before
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drug administration.  Subjects were excluded
from participating in the study if they were
allergic to fluoroquinolone antibiotics or heparin
or if women were breast-feeding, pregnant, or
intending to become pregnant within 30 days of
the study period.  All subjects underwent a
screening evaluation based on medical history,
physical examination, routine serum chemistry,
and urinalysis.  Clinically significant abnor-
malities in any of these tests were criteria for
exclusion from study participation.
All subjects provided written informed consent
before enrollment, and the study was approved




Male and female volunteers were stratified by
an estimated body mass index (BMI [kg/m2])
calculation (Equation 1).13 In addition, ideal
body weight (IBW [kg]), lean body weight (LBW
[kg]), and body surface area (BSA [m2]) were
estimated for all study subjects by using
Equations 2–4.14–16 Weight is in kilograms and
height is in meters, unless otherwise indicated.
(Eq. 1) BMI = weight/height2
(Eq. 2) IBWmen = 50 + 2.3(height – 60), and
IBWwomen = 45.5 + 2.3(height – 60),
where height is in inches
(Eq. 3) LBWmen = (1.10 • weight) –
128[weight2⁄(100 • height)2]
LBWwomen = (1.07 • weight) –
148[weight2⁄(100 • height)2]
(Eq. 4) BSA = weight0.425 • height0.725 • 0.20247
Study Protocol
Subjects were instructed to avoid alcohol,
caffeine, fruit, and fruit juices 24 hours before
and during the entire study period.  On the
morning of the study, after an 8-hour fast,
subjects reported to the Indiana University
General Clinical Research Center (GCRC), where
on arrival a venous catheter was inserted into a
forearm vein of each arm.  Each subject received
levofloxacin (Levaquin; Ortho-McNeil
Pharmaceutical, Inc., South Raritan, NJ) as a
single 500-mg dose administered with an
intravenous infusion pump over 60 minutes.
Subjects continued to fast for an additional 4
hours after the end of the infusion.  Venous
blood samples (10 ml) were obtained from the
indwelling catheter contralateral to the infusion
arm, into evacuated blood collection tubes that
contained no anticoagulant, immediately before
and at 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, and
36 hours after the infusion.  The venous catheter
was removed at 24 hours, and blood samples
obtained at 36 hours after the infusion were
obtained by a separate venipuncture.  Blood was
allowed to clot; serum was separated by
centrifugation and stored at -70°C until analysis.
Subjects were instructed to void before drug
administration, and urine was collected for the
entire 36-hour study period:  between 0 and 24
hours in the GCRC and between 24 and 36 hours
as an outpatient.  The volume was determined,
and an aliquot was stored at -70°C until analysis.
Sample Analysis
Levofloxacin concentrations in serum and
urine were determined by a modified reverse-
phase high-performance liquid chromatography
method with ultraviolet detection, as previously
described for the quantification of levofloxacin in
serum.17 Serum samples were thawed at room
temperature and vortexed for 30 seconds, and a
50-µl aliquot was collected.  After addition of a
displacing reagent (acetonitrile-water [20:80,
volume:volume ratio, v:v] containing 0.5%
sodium dodecyl sulfate [SDS] and 0.075 mol/L
phosphate) containing the internal standard
(ciprofloxacin; Bayer, West Haven, CT), serum
samples were ultrafiltered with an Amicon
Centrifree apparatus (Amicon Division, W.R.
Grace & Co., Beverly, MA).  The ultrafiltrates
were then injected onto an Adsorbosphere HS
C18 column (particle size 5 µm, 4.6 x 250 mm;
Alltech Associates, Deerfield, IL) with ultraviolet
detection (280 nm).  The mobile phase consisted
of acetonitrile-water (40:60 v:v) containing 0.01
mol/L SDS, 0.01 mol/L tetrabutylammonium
acetate, and 0.025 mol/L citric acid. The serum
standard curves were linear over the calibration
range of 0.1–10 mg/L with a lower limit of
detection of 0.375 mg/L.  Serum samples greater
than 10 mg/L were diluted 2-fold and reanalyzed.
At quality control serum concentrations of 0.375,
1.50, and 6.00 mg/L, interday and intraday
coefficients of variation were 7% or less.
The equipment and conditions for the urine
levofloxacin assay were identical to those
described for the serum assay.  Urine samples
were thawed and vortexed for 30 seconds, and a
50-µl aliquot was diluted with 1000 µl of mobile
phase.  Fifty microliters of internal standard
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(ciprofloxacin 30 µg/ml) were added to the
diluted sample and vortexed for an additional 30
seconds before being transferred to a vial and
directly injected onto the column for analysis.
The urine calibration curve was linear from
1–500 mg/L with a lower limit of detection of
3.75 mg/L.  At urine quality control concentrations
of 3.75, 37.5, and 375 mg/L, interday and
intraday coefficients of variation were 12% and
9% or less, respectively.
Serum and urine creatinine concentrations
were determined by a colorimetric method using
a COBAS-Mira spectrophotometer (Roche, Basel,
Switzerland) in the Indiana University GCRC
core analytical laboratory.  Interday and intraday
coefficients of variation were 5% or less.  The 24-
hour creatinine clearance (Clcr) values were
calculated from the urine collection by standard
methods.
Pharmacokinetic Analysis
Pharmacokinetic parameters were estimated by
fitting pharmacokinetic models to the levo-
floxacin serum concentration-time data by using
maximum likelihood estimation in ADAPT II,
release 4.18 The variance model assumed that the
standard deviation of the residuals was linear
with increasing concentrations using Equation 5:
(Eq. 5) ƒ(V) = [yint + m(y)]2
where yint is the y intercept of the residual plot
and m is the slope of the line.  The y intercept
was initially fixed at one half of the lower limit of
detection for the levofloxacin serum assay and
estimated with the combined residuals from all
subjects from the final two-compartment model.
The slopes were initially set at 10% and estimated
in each individual subject.
Model discrimination was accomplished by
visual inspection of the distribution of the
weighted residuals, Akaike information criteria,19
sums of the squared weighted residuals, and
visual inspection of the predicted versus
measured data.  The pharmacokinetic model that
was best fit to the serum concentration-time data
was a two-compartment model with first-order
elimination from the central compartment.  The
model was parameterized by using apparent
volume of distribution of the central compart-
ment (Vc), apparent volume of distribution of the
peripheral compartment (Vp), Cls, and
distribution clearance between the central and
peripheral compartments (Cld).
Secondary pharmacokinetic parameters derived
from model estimates including terminal
elimination half-life (t1⁄2) were calculated by
standard methods.20 Apparent Vss and renal
clearance (Clr) were calculated with Equations 6
and 7, respectively:
(Eq. 6) Vss = Vc + Vp
(Eq. 7) Clr = Ae0–36 ⁄AUC0–36
where Ae0–36 is the amount of levofloxacin
excreted in the urine from 0–36 hours after
administration and AUC0–36 is the area under the
concentration-time curve from 0–36 hours.  The
area under the levofloxacin concentration-time
curve from time zero to infinity (AUC0–∞) and
AUC0–36 were calculated by the integration of the
model-derived concentration-time curves.  The
levofloxacin Cmax was obtained by visual
inspection of each subject’s model-derived
concentration-time profile.
Statistical Analysis
Statistical analyses were performed by using
SigmaStat for Windows, version 2.03 (SPSS Inc.,
Chicago, IL). Statistical comparisons of
pharmacokinetic parameter estimates between
men and women were performed with the
Wilcoxon rank sum test.  Univariate least squares
linear regression was used to examine the
relationship between Cls and Vss of levofloxacin
with Clcr, body mass index, ideal body weight,
lean body weight, body surface area, and total
body weight in men and women.  Overall
differences were considered statistically signifi-
cant at a p value less than 0.05.
Results
The study group was composed of 20 healthy
volunteers:  11 men aged 19–39 years (median
27 yrs) and 9 women aged 19–37 years (median
31 yrs).  All 20 participants successfully
completed the study without any clinically
significant adverse effects and were included in
the data analysis.  Eight subjects were self-
reported Caucasian (six men, two women), three
African-American (two men, one woman), seven
Asian (two men, five women), and two Hispanic
(one man, one woman).  Individual body mass
indexes and total body weights in men and
women are depicted in Figure 1.  Subject
demographics including body surface area, ideal
body weight, and lean body weight in the study
groups are displayed in Table 1.  The mean ± SD
24-hour Clcr values for men and women were
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105.7 ± 33.6 and 97.0 ± 37.5 ml/minute,
respectively (p=0.59).
The final pharmacokinetic model fit to the data
was a two-compartment open model with first-
order elimination from the central compartment.
The median (range) R2 for individual fits with the
final model was 0.996 (0.990–0.999).
Levofloxacin serum concentration versus time
data obtained from a representative male subject
and female subject with the fitted serum
concentration-time curve are shown in Figure 2.
The representative subjects had similar estimated
pharmacokinetic parameters to those of the
medians obtained from each study group.
Model-estimated pharmacokinetic parameters
after intravenous levofloxacin administration are
presented in Table 2.  The Cls of levofloxacin was
significantly (p<0.01) slower in women
compared with that in men.  Similarly, women
had a 40% slower Clr of levofloxacin despite a
comparable (p=0.61) 24-hour Clcr. The nonrenal
clearance (i.e., Cls – Clr) was not significantly
different between men and women of this study
(p=0.72, data not shown).  The Vss and Vc of
levofloxacin were significantly (p<0.01) smaller
in women, in concert with a significant 25%
increase in the median levofloxacin Cmax.
Women had a 24% increase in the total exposure
to levofloxacin as determined by a significantly
larger AUC0–∞. The Cld and t1/2 for levofloxacin
were not significantly different between sexes
(p=0.56 and 0.06, respectively).
The individual pharmacokinetic parameter
estimates were used to simulate the predicted
steady-state levofloxacin serum concentrations in
each subject.  The mean ± SD steady-state
levofloxacin concentrations were estimated by
the predicted steady-state concentrations in men
and women separately. Figure 3 displays the
mean ± SD predicted steady-state levofloxacin
concentrations after a 5-day regimen of
intravenous levofloxacin 500 mg administered by
a 60-minute infusion every 24 hours.
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Table 1.  Demographics of the Study Subjects
Men Women
(n=11) (n=9) p Value
Body mass index (kg/m2) 23.2 (19.9–28.3) 23.6 (16.0–32.4) 0.67
Total body weight (kg) 74.8 (57.1–92.3) 64.1 (51.2–79.9) 0.03
Height (cm) 177 (154–198) 168 (157–180) 0.03
Body surface area (m2) 1.93 (1.54–2.24) 1.67 (1.53–1.85) 0.02
Ideal body weight (kg) 72.0 (51.0–91.0) 60.0 (50.0–70.0) <0.01
Lean body weight (kg) 60.0 (45.0–72.0) 45.0 (40.0–51.0) <0.01
Data are median (range).
Figure 1. Body mass index (A) and total body weight (B) of
the study participants.  The medians are identified by (–).
Figure 2.  Levofloxacin concentration-time profiles after a
60-minute intravenous infusion of levofloxacin 500 mg, in a
representative male (l) and female (m) subject.  Symbols
represent observed concentration values, with a fitted line
depicting the serum levofloxacin concentrations predicted
from the pharmacokinetic model.  Insert displays the
concentration-time curve on a log-linear scale.
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The univariate linear regression analysis
revealed a positive relationship between total
body weight and Vss of levofloxacin in the
combined sexes (R2=0.67, 20 subjects, p<0.05),
in men (R2=0.79, 11 subjects, p<0.05), and in
women (R2=0.46, 9 subjects, p<0.05) alone.
Figure 4A shows the relationship between Vss
and total body weight in men and women,
separately.  For any given body weight of men in
this study, women of the same weight had a
smaller Vss for levofloxacin.  Furthermore, the
univariate regression analyses of Vss displayed
positive relationships versus body mass index
(men R2=0.18, women R2=0.31), lean body
weight (men R2=0.77, women R2=0.55), body
surface area (men R2=0.77, women R2=0.42), and
ideal body weight (men R2=0.52, women
R2=0.06).  Lean body weight had the strongest
relationship with Vss in men, women, and the
combined sexes (R2=0.87, 20 subjects, p<0.05;
Figure 4B).
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Table 2.  Pharmacokinetic Parameter Estimates for Levofloxacin in Men and Women
Men Women
Parameter (n=11) (n=9) p Value
Cls (L/hr) 11.0 (9.33–16.5) 8.87 (7.90–10.7) <0.01
Clr (L/hr) 10.4 (7.65–13.5) 6.31 (4.52–9.33) <0.01
Vc (L) 58.4 (25.5–84.7) 22.0 (7.34–74.6) <0.01
Vss (L) 117 (93.3–152) 81.0 (59.7–105) <0.01
Cld (L/hr) 73.9 (7.57–560) 75.5 (1.99–399) 0.56
t1/2 (hr) 7.3 (6.4–9.4) 6.4 (5.4–13) 0.06
Cmax (mg/L) 5.4 (4.7–6.2) 6.7 (5.9–13) <0.01
AUC0–∞ (mg•hr/L) 45.5 (30.3–53.6) 56.4 (46.8–63.3) <0.01
Data are median (range).
Cls = systemic clearance; Clr = renal clearance; Vc = central compartment volume of distribution; Vss
= steady-state volume of distribution; Cld = intercompartmental distribution clearance; t1/2 = terminal
elimination half-life; Cmax = maximum serum concentration; AUC0–∞ = area under the concentration-
time curve from time zero to infinity.
Figure 3.  Predicted mean ± SD steady-state serum
levofloxacin concentration versus time curve generated
from individual simulations of the pharmacokinetic
parameter estimates in all study subjects.  The symbols
represent the predicted mean ± SD levofloxacin serum
concentrations in men (l ) and women (m ) at the
predetermined blood sampling times, with a smooth curve
though each of the mean values.



































Table 3.  Body Weight–Adjusted Pharmacokinetic Parameter Estimates for Levofloxacin
Men Women
Parameter (n=11) (n=9) p Value
Normalized for
total body weight
Cls (L/hr/kg) 0.16 (0.12–0.19) 0.15 (0.10–0.17) 0.36
Vss (L/kg) 1.62 (1.33–1.72) 1.31 (1.01–1.47) <0.01
Normalized for
lean body weight
Cls (L/hr/kg) 0.20 (0.16–0.24) 0.20 (0.17–0.21) 0.88
Vss (L/kg) 2.00 (1.75–2.20) 1.74 (1.39–2.10) <0.01
Data are median (range).
Cls = systemic clearance; Vss = steady-state volume of distribution.
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Systemic clearance and total body weight also
displayed a positive relationship in the combined
sexes (R2=0.53, 20 subjects, p<0.01).  However,
as depicted in Figure 4C, differences in total
body weight accounted for only 19% of the total
variation of the Cls in women and 52% in men.
The Cls of levofloxacin also displayed a positive
relationship with measures of body mass index
(men R2=0.23, women R2=0.04), lean body
weight (men R2=0.44, women R2=0.61), body
surface area (men R2=0.42, women R2=0.40), and
ideal body weight (men R2=0.20, women
R2=0.05).  As seen with the relationship with Vss,
lean body weight had the strongest relationship
with Cls in men, women, and the combined sexes
(R2=0.66, 20 subjects, p<0.05; Figure 4D).
Primary pharmacokinetic parameter estimates
were normalized to total body weight and lean
body weight, which displayed the strongest
relationship with both Cls and Vss. Table 3
displays the lean and total body weight-adjusted
Cls and Vss for men and women.  Sex-based
differences in levofloxacin Cls and Clr were
attenuated and no longer statistically significant
when adjusted for total body weight (p=0.36 and
0.50, respectively) or lean body weight (p=0.88
and 0.91, respectively).  However, Vss normalized
to lean or total body weight remained
significantly smaller (p<0.01) in women
compared with that in men, suggesting that sex-
based differences in Vss may exist.
Discussion
Before this investigation, to our knowledge, the
sex-based pharmacokinetics of levofloxacin after
intravenous administration had not been
characterized.  In this study, we examined the
disposition of systemically administered
levofloxacin in a population of men and women
who were stratified by body mass index.  Results
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Figure 4. Relationship between levofloxacin steady-state volume of distribution (Vss) and total body weight (A), and Vss and
lean body weight (B) in men (l) and women (m).  Relationship between levofloxacin systemic clearance (Cls) and total body
weight (C), and Cls and lean body weight (D) in men and women.  Solid lines represent the univariate linear regression least
squares fit for men and women separately and dashed lines represent the linear regression analyses for the combined study
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indicated that, after intravenous administration,
levofloxacin Cmax is considerably higher in
women than in men of a similar body mass
index.  In addition, women displayed a greater
exposure to levofloxacin due to a slower Cls
which corresponded to a median AUC0–∞ that
was 24% higher than that of men.
The significantly slower Cls of levofloxacin in
women can predominantly be attributed to a
slower Clr of similar magnitude.  However, the
24-hour Clcr was not statistically significantly
different between men and women in this study.
In addition, Clcr was not a strong predictor of the
Clr of levofloxacin (R2=0.17, data not shown).
Therefore, it is likely that the disparities in Clr
are due to differences in the tubular secretion
and/or reabsorption of levofloxacin between the
sexes, since it is not highly protein bound.
Potential differences in tubular secretion and
reabsorption have not been well studied between
the sexes despite reports that suggest differing
renal handling of certain drugs between men and
women.21 Levofloxacin, however, has been
shown to be a substrate for drug transporters in
vitro, which have known activity in renal
tubules.22 There is no evidence of sex-related
differences in active transport proteins such as
the multidrug-resistant–associated protein or the
organic anion transporters in humans, but
differences have been reported in animal models
and may have contributed to the findings of this
study.23
The higher levofloxacin Cmax observed in
women can be attributed to a significantly
smaller median Vc. Specifically, the pharmaco-
kinetic analysis revealed that women have both
smaller Vc and Vss of levofloxacin, despite an
average body mass index similar to that of the
male study group.  On average, women did weigh
less than the men in this investigation, regardless
of similar body mass indexes.  Nonetheless, the
total body weight–adjusted Vss was significantly
smaller (p<0.01) in women.  However, the Vss
normalized to total body weight should be
cautiously interpreted since a distinct
relationship between Vss and total body weight
was observed in men versus women (Figure 4A).
Total body weight, therefore, was not found to be
the best size descriptor for normalization of
levofloxacin Vss between the sexes.  Furthermore,
normalization of levofloxacin Vss to total body
weight may have biased the conclusions of
previous pharmacokinetic investigations of
levofloxacin.2, 24
The estimate of lean body weight was the
strongest predictor of Vss in men and women
combined.  Furthermore, a similar relationship
between lean body weight and Vss was observed
in men and women separately.  Lean body weight
differs from ideal body weight and is an
estimation of bone, organ, and muscle tissue
mass.  Theoretically, ideal body weight can
approach but never reach lean body weight in
any given individual.  It is not surprising that
lean body weight was found to be a strong
predictor of Vss in men, women, and the
combined sexes since fluoroquinolones distribute
more rapidly and to a greater extent into lean
muscle as opposed to adipose tissue.2, 25–28 In fact,
this property may in part explain the smaller Vc and
subsequent larger Cmax after levofloxacin
administration in women compared with these
parameters in men.  Men on average have an
increased amount of body water and an increased
muscle mass:body fat ratio compared with
women.21 It would therefore be expected that
men would have a greater tissue distribution of
levofloxacin and subsequent lower serum
concentrations than women, as observed in our
study.  These observations coupled with the
differential predictive power of total body weight
in men versus women lend strong support for a
lean body weight normalization of levofloxacin
Vss for comparison between the sexes. 
Women appear to be more susceptible to
fluoroquinolone toxicity than are men, especially
in the central nervous system.3, 6, 29 Levofloxacin,
however, is a fairly well tolerated fluoro-
quinolone with a low rate of adverse effects that
occur in a concentration-dependent manner.
Although increased serum levofloxacin
concentrations may result in an increased rate of
toxicity in women, fluoroquinolones are
concentration-dependent bactericidal agents.
Therefore, lower average serum concentrations
and decreased levofloxacin exposure in men
could result in inadequate antimicrobial activity
against bacterial strains moderately susceptible to
levofloxacin.  This supports the performance of
clinical investigations into the efficacy of
levofloxacin in men versus women in a large
population of patients.
Conclusion
Compared with men of a similar body mass
index, women have a slower Cls and smaller Vss
of levofloxacin after intravenous administration.
These differences lead to a greater drug exposure
and higher Cmax, respectively, in women.  Lean
1317
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body weight had the strongest relationship with
both Cls and Vss in our study.  Nevertheless, after
normalization to lean body weight, Vss remained
significantly smaller in women, suggesting a
difference in the pharmacokinetics.  Therefore,
fixed intravenous doses of levofloxacin will lead
to higher Cmax in women than in men.  This may
place women at an increased risk of fluoro-
quinolone toxicity compared with men but also
may necessitate larger doses in men to observe
similar antimicrobial efficacy.  Therefore,
levofloxacin dosage adjustments based on sex or
lean body weight should be considered on an
individual basis depending on location of
infection, susceptibility of the causative
microorganism, patient’s renal function, and risk
for the development of fluoroquinolone toxicity.
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